HIGHLIGHTS
- What: The authors provide health education and regular follow-up to all enrolled MAFLD patients. The main reason the authors believe is the lack of effective drugs for MASH, so it is very difficult for MASH patients to achieve fibrosis regression as much as CHB patients. Page 13/24 This study has a few limitations.
- Who: Metabolic dysfunction-associated steatohepatitis and colleagues from the Beijing Friendship Hospital,Capital Medical have published the paper: Delicate and thin fibrous septa indicate a regression tendency in metabolic dysfunction-associated steatohepatitis patients with advanced fibrosis, in the Journal: (JOURNAL . . .

If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.